Form 4: Akoya Biosciences CFO, John Frederick Ek, Reports Stock Transactions

Akoya Biosciences CFO, John Frederick Ek, acquired 87,500 shares of common stock and reports holding 268,228 shares directly and 20,000 shares indirectly through a trust.

Summary

• John Frederick Ek, the CFO of Akoya Biosciences, Inc., reported a transaction involving the company's common stock.
• On November 19, 2024, Mr. Ek acquired 87,500 shares of common stock.
• These shares were acquired at a price of $0, indicating they were likely granted as restricted stock units.
• Following this transaction, Mr. Ek directly owns 268,228 shares of Akoya Biosciences common stock.
• Additionally, Mr. Ek indirectly owns 20,000 shares through the Ek Trust dated November 20, 2020.

Sentiment

Score: 6

Explanation: The document is a routine filing of stock transactions by a company executive. It is neither particularly positive nor negative, but rather a standard disclosure.

Positives

• The acquisition of shares by the CFO could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders reporting changes in their beneficial ownership of company stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider trading.
• The reporting of restricted stock unit grants is common for executive compensation packages in the biotechnology industry, similar to practices at companies like Illumina and Bio-Rad.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it indicates the CFO's confidence in the company.

Key Dates

Keywords

Akoya Biosciences, John Frederick Ek, CFO, stock transaction, restricted stock units, beneficial ownership, equity